First Tracks Biotherapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Dan Faga
Chief executive officer
US$6.1m
Total compensation
| CEO salary percentage | 11.51% |
| CEO tenure | less than a year |
| CEO ownership | 1.4% |
| Management average tenure | less than a year |
| Board average tenure | no data |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$169m |
| Dec 31 2025 | US$6m | US$706k | -US$166m |
| Dec 31 2024 | US$14m | US$685k | -US$164m |
Compensation vs Market: Dan's total compensation ($USD6.13M) is above average for companies of similar size in the US market ($USD3.70M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Faga (46 yo)
Mr. Daniel R. Faga, also known as Dan, is President, chief executive officer and Director of AnaptysBio, Inc. from August 2023. He was Interim President & CEO and Director of AnaptysBio, Inc. from March 21...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$6.13m | 1.42% $ 8.7m | |
| Chief Medical Officer | less than a year | US$2.37m | 0.12% $ 743.3k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Business Officer | no data | no data | 0.049% $ 300.7k | |
| Secretary | no data | no data | no data |
Experienced Management: TRAX's management team is not considered experienced ( 0.2 years average tenure), which suggests a new team.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/21 23:46 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
First Tracks Biotherapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Emily Bodnar | H.C. Wainwright & Co. |
| Anupam Rama | J.P. Morgan |